Mark C. Eagleton

442 total citations
7 papers, 279 citations indexed

About

Mark C. Eagleton is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Mark C. Eagleton has authored 7 papers receiving a total of 279 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 4 papers in Molecular Biology and 2 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Mark C. Eagleton's work include Bone health and treatments (6 papers), Bone Metabolism and Diseases (4 papers) and Radiopharmaceutical Chemistry and Applications (2 papers). Mark C. Eagleton is often cited by papers focused on Bone health and treatments (6 papers), Bone Metabolism and Diseases (4 papers) and Radiopharmaceutical Chemistry and Applications (2 papers). Mark C. Eagleton collaborates with scholars based in United States, India and United Kingdom. Mark C. Eagleton's co-authors include Katherine N. Weilbaecher, David Piwnica‐Worms, Angela C. Hirbe, Julie L. Prior, Özge Uluçkan, Elizabeth A. Morgan, Anthony J. Apicelli, Desiree H. Floyd, Hongju Deng and Kathryn Trinkaus and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Blood.

In The Last Decade

Mark C. Eagleton

7 papers receiving 275 citations

Peers

Countries citing papers authored by Mark C. Eagleton

Since Specialization

Citations

This map shows the geographic impact of Mark C. Eagleton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark C. Eagleton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark C. Eagleton more than expected).

Fields of papers citing papers by Mark C. Eagleton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark C. Eagleton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark C. Eagleton. The network helps show where Mark C. Eagleton may publish in the future.

Co-authorship network of co-authors of Mark C. Eagleton

This figure shows the co-authorship network connecting the top 25 collaborators of Mark C. Eagleton. A scholar is included among the top collaborators of Mark C. Eagleton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark C. Eagleton. Mark C. Eagleton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

#	Work	Indexed citations
1	The ARF Tumor Suppressor Regulates Bone Remodeling and Osteosarcoma Development in Mice 2010 ·PLoS ONE ·Daniel A. Rauch, Michelle A. Hurchla, John C. S. Harding, Hongju Deng, Lauren Shea, Mark C. Eagleton, Stefan Niewiesk, Michael D. Lairmore, David Piwnica‐Worms, Thomas J. Rosol, Jason D. Weber, Lee Ratner, Katherine N. Weilbaecher	18
2	The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts 2009 ·Bone ·Angela C. Hirbe, Anke J. Roelofs, Desiree H. Floyd, Hongju Deng, (unknown), Lisa G. Lanigan, Anthony J. Apicelli, Zhiqiang Xu, Julie L. Prior, Mark C. Eagleton, David Piwnica‐Worms, Michael J. Rogers, Katherine N. Weilbaecher	54
3	Interferon-γ Targets Cancer Cells and Osteoclasts to Prevent Tumor-associated Bone Loss and Bone Metastases 2008 ·Journal of Biological Chemistry ·Zhiqiang Xu, Michelle A. Hurchla, Hongju Deng, Özge Uluçkan, (unknown), (unknown), Mark C. Eagleton, Emanuela Heller, Desiree H. Floyd, Wessel P. Dirksen, Sherry T. Shu, Yuetsu Tanaka, Soledad Fernández, Thomas J. Rosol, Katherine N. Weilbaecher	37
4	APT102, a novel adpase, cooperates with aspirin to disrupt bone metastasis in mice 2008 ·Journal of Cellular Biochemistry ·Özge Uluçkan, Mark C. Eagleton, Desiree H. Floyd, Elizabeth A. Morgan, Angela C. Hirbe, Matthew Kramer, (unknown), Julie L. Prior, David Piwnica‐Worms, (unknown), (unknown), Katherine N. Weilbaecher	48
5	P7. The ADP receptor P2Y12 is expressed in developing osteoclasts and is required for full osteoclast function and tumor associated osteolysis 2008 ·Cancer Treatment Reviews ·Desiree H. Floyd, (unknown), Angela C. Hirbe, Özge Uluçkan, Mark C. Eagleton, (unknown), Katherine N. Weilbaecher	2
6	Disruption of CXCR4 enhances osteoclastogenesis and tumor growth in bone 2007 ·Proceedings of the National Academy of Sciences ·Angela C. Hirbe, (unknown), Özge Uluçkan, Elizabeth A. Morgan, Mark C. Eagleton, Julie L. Prior, David Piwnica‐Worms, Katherine N. Weilbaecher	44
7	Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent manner 2006 ·Blood ·Angela C. Hirbe, Özge Uluçkan, Elizabeth A. Morgan, Mark C. Eagleton, Julie L. Prior, David Piwnica‐Worms, Kathryn Trinkaus, Anthony J. Apicelli, Katherine N. Weilbaecher	76

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact